Penumbra
About: Penumbra Inc develops and manufactures medical devices for the neurovascular and peripheral vascular markets. Its products are sold to hospitals and are developed for use by specialist physicians. Within the neurovascular business, the firm offers products for neurovascular access, ischemic stroke, neurovascular embolization, and neurosurgical tool markets. In the peripheral vascular business, the firm sells devices related to peripheral embolization and peripheral thrombectomy. It operates as one reportable segment and its business activity consists of the design, development, manufacturing and marketing of inventive medical products.
Employees: 4,500
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
562% more call options, than puts
Call options by funds: $63.7M | Put options by funds: $9.62M
172% more first-time investments, than exits
New positions opened: 68 | Existing positions closed: 25
100% more funds holding in top 10
Funds holding in top 10: 2 [Q3] → 4 (+2) [Q4]
22% more capital invested
Capital invested by funds: $6.8B [Q3] → $8.3B (+$1.5B) [Q4]
12% more funds holding
Funds holding: 329 [Q3] → 367 (+38) [Q4]
0.97% more ownership
Funds ownership: 90.0% [Q3] → 90.97% (+0.97%) [Q4]
8% less repeat investments, than reductions
Existing positions increased: 121 | Existing positions reduced: 131
Research analyst outlook
11 Wall Street Analysts provided 1 year price targets over the past 3 months
11 analyst ratings
RBC Capital Shagun Singh 46% 1-year accuracy 31 / 68 met price target | 13%upside $330 | Outperform Maintained | 24 Apr 2025 |
UBS Priya Sachdeva 50% 1-year accuracy 2 / 4 met price target | 13%upside $330 | Buy Maintained | 24 Apr 2025 |
Truist Securities David Rescott 59% 1-year accuracy 10 / 17 met price target | 13%upside $330 | Buy Maintained | 24 Apr 2025 |
Stifel Mathew Blackman 41% 1-year accuracy 7 / 17 met price target | 9%upside $318 | Buy Maintained | 24 Apr 2025 |
Wells Fargo Larry Biegelsen 27% 1-year accuracy 12 / 44 met price target | 8%upside $315 | Overweight Maintained | 24 Apr 2025 |
Financial journalist opinion
Based on 19 articles about PEN published over the past 30 days
